This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

5 Health Care Stocks Setting Up to Break Out


One of those is Pfizer (PFE - Get Report), the big pharma giant that's behind blockbuster drugs like Celebrex and Viagra. Like Abbott, Pfizer is forming an inverse head and shoulders pattern. Unlike ABT, Pfizer's setup is less far along, giving investors an opportunity to get in earlier.

It's worth noting that patterns like Pfizer's inverse head-and-shoulders setup don't work because of mystical forces or the shape of the setup; at the end of the day, it just comes down the buyers and sellers, supply and demand. For Pfizer, we know that there has historically been a glut of sellers at an above the $23 level (the neckline), so a breakout above $23 sends an important message: It tells us that increasingly eager buyers have absorbed all of the supply of shares that previously were offered at that level.

>>5 Dividend Stocks Ready to Boost Payouts

That's part of why the inverse head and shoulders is commonly described as a pattern that depicts exhaustion among sellers.

Declining volume for Pfizer is actually a good sign for shares -- it means that participation in PFE has been declining as the pattern progressed and PFE consolidated. A volume spike on a break above $23 (like the one in ABT) is a good sign that the move is valid. Wait for that to happen before buying shares.

Pfizer, one of Lee Ainslie's Maverick Capital holdings, shows up on a recent list of 5 Buy-Rated Stocks Outyielding the 10-Year.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ABT $47.79 0.38%
AGN $232.71 0.13%
BKD $37.36 0.73%
MDT $78.55 -0.33%
PFE $34.61 0.06%


DOW 18,190.72 -23.70 -0.13%
S&P 500 2,109.74 -1.00 -0.05%
NASDAQ 4,982.1270 -5.7630 -0.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs